Physician Payments from Industry Are Associated with Greater Medicare Part D Prescribing Costs
about
Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.Structure and activities of Pharmacy and Therapeutics Committees among Public Hospitals in South Africa; findings and implications.Disclosure of industry payments to prescribers: industry payments might be a factor impacting generic drug prescribing.Association Between Academic Medical Center Pharmaceutical Detailing Policies and Physician Prescribing.Influence of pharmaceutical marketing on Medicare prescriptions in the District of Columbia.Exploring unnecessary invasive procedures in the United States: a retrospective mixed-methods analysis of cases from 2008-2016.Gynaecologists and industry: ain't no sunshine.Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.The Receipt of Industry Payments is Associated with Prescribing Promoted Alpha-Blockers and Overactive Bladder Medications.Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data.Getting more light into the dark room of editorial conflicts of interest.Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries.Conflicts of interest of editors of medical journals.A cross-sectional study of all clinicians' conflict of interest disclosures to NHS hospital employers in England 2015-2016.Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry's Disclosure UK database, 2015 and 2016 cohorts
P2860
Q38641699-B32CFB90-F49E-42A8-81A6-6DA132D11708Q38646978-6404E967-5959-402D-9C43-AAE20B8413F1Q38796535-224913DC-0E6A-42F7-AD9A-08FB5C35BDD3Q38808785-09727CC3-C8B3-4FED-90C2-75BFAEB9F9A8Q42699082-6FF2A489-C659-4598-B679-2663FF5464AAQ47143253-FD46D12B-248D-4243-9437-35D404E69B67Q47738447-79D9A29E-AC45-4920-A7CD-3E0553B72739Q47852975-5AFD55F8-4A32-4D87-9D0C-FC59E125D66CQ52572355-880E7034-1B9F-4706-96D6-6956C791E494Q52612467-AC8F35CC-7657-4831-97FD-425029D6E9A9Q55040246-21E771D3-8094-4890-88FA-7BDC01F29063Q55342152-23DEF650-FB0D-46FC-A246-630B568E3558Q55363483-5EC097D3-9235-4FBA-BD73-9A9173D54C51Q55378736-1760838C-9216-4793-87EB-FBB65BDCE92FQ57806288-589ACF3A-8531-43E5-91BB-3F79CDD49CC1
P2860
Physician Payments from Industry Are Associated with Greater Medicare Part D Prescribing Costs
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Physician Payments from Indust ...... icare Part D Prescribing Costs
@ast
Physician Payments from Indust ...... icare Part D Prescribing Costs
@en
Physician Payments from Indust ...... icare Part D Prescribing Costs
@nl
type
label
Physician Payments from Indust ...... icare Part D Prescribing Costs
@ast
Physician Payments from Indust ...... icare Part D Prescribing Costs
@en
Physician Payments from Indust ...... icare Part D Prescribing Costs
@nl
prefLabel
Physician Payments from Indust ...... icare Part D Prescribing Costs
@ast
Physician Payments from Indust ...... icare Part D Prescribing Costs
@en
Physician Payments from Indust ...... icare Part D Prescribing Costs
@nl
P2860
P3181
P1433
P1476
Physician Payments from Indust ...... icare Part D Prescribing Costs
@en
P2093
Clifford S Perlis
Roy H Perlis
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0155474
P407
P577
2016-01-01T00:00:00Z